Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.480
-0.170 (-3.66%)
At close: Sep 16, 2026, 4:00 PM EDT
4.460
-0.020 (-0.45%)
After-hours: Sep 16, 2026, 4:10 PM EDT
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,002,393
Profits / Employee
-$2,708,703
Market Cap
105.09M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | 2 | 33.33% |
| Dec 31, 2022 | 6 | 0 | - |
| Sep 30, 2022 | 6 | 0 | - |
| Jun 30, 2022 | 6 | - | - |
| Dec 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Adicet Bio | 102 |
| PolyPid | 75 |
| Connect Biopharma Holdings | 64 |
| PMV Pharmaceuticals | 54 |
| Vivani Medical | 42 |
| Oncolytics Biotech | 29 |
COYA News
- 1 day ago - Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial - TheFly
- 1 day ago - Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 8 days ago - Coya announces publication of preclinical study on effects of COYA 303 - TheFly
- 8 days ago - Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - Business Wire
- 15 days ago - Coya Therapeutics Slides: Investor presentation - Filings
- 5 weeks ago - Coya Therapeutics reports Q2 EPS (28c), consensus (36c) - TheFly
- 5 weeks ago - Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
- 5 weeks ago - Coya Therapeutics Quarterly report: Q2 2026 - Filings